NPI: 1184620486 · HASTINGS, PA 16646 · General Acute Care Hospital · NPI assigned 06/22/2005
Authorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
| Authorized Official | LAWRENCE, CHARLOTTE (SECRETARY) |
| NPI Enumeration Date | 06/22/2005 |
Other providers sharing the same authorized official: LAWRENCE, CHARLOTTE
| Year | Claims | Total Paid |
|---|---|---|
| 2020 | 4,544 | $113K |
| 2021 | 28,827 | $756K |
| 2022 | 8,418 | $312K |
| 2023 | 9,998 | $342K |
| 2024 | 8,823 | $341K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 5,683 | 5,433 | $437K |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1,675 | 1,532 | $246K |
| 99284 | Emergency department visit for the evaluation and management, high severity | 2,299 | 2,180 | $245K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2,160 | 2,089 | $191K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4,069 | 3,946 | $159K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1,662 | 1,617 | $59K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 325 | 306 | $51K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 3,378 | 2,053 | $50K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 440 | 408 | $38K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2,451 | 2,357 | $31K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 775 | 753 | $28K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4,468 | 3,997 | $24K |
| 80053 | Comprehensive metabolic panel | 2,055 | 1,886 | $22K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 226 | 199 | $20K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1,986 | 1,924 | $20K |
| 80050 | General health panel | 363 | 352 | $18K |
| 84443 | Thyroid stimulating hormone (TSH) | 584 | 569 | $14K |
| 70450 | Computed tomography, head or brain; without contrast material | 221 | 204 | $13K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 311 | 309 | $13K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1,416 | 1,295 | $13K |
| 71046 | Radiologic examination, chest; 2 views | 806 | 757 | $11K |
| 80061 | Lipid panel | 706 | 694 | $11K |
| 36415 | Collection of venous blood by venipuncture | 4,827 | 4,250 | $10K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 115 | 99 | $9K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 42 | 41 | $8K |
| 84703 | 612 | 593 | $7K | |
| 84484 | 830 | 580 | $6K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 830 | 776 | $6K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 697 | 650 | $5K |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | 14 | 14 | $5K |
| T1015 | Clinic visit/encounter, all-inclusive | 103 | 39 | $4K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 303 | 217 | $4K |
| 93000 | 552 | 520 | $4K | |
| 84439 | 493 | 470 | $4K | |
| 85730 | 570 | 525 | $4K | |
| 83605 | 540 | 468 | $3K | |
| 83735 | 536 | 474 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 406 | 397 | $3K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 405 | 389 | $3K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 87 | 66 | $3K |
| 83690 | 666 | 618 | $3K | |
| 83880 | 120 | 104 | $3K | |
| 80076 | 338 | 312 | $3K | |
| 81001 | 1,008 | 961 | $3K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 28 | 28 | $3K |
| 85027 | 329 | 310 | $2K | |
| 85610 | 707 | 606 | $2K | |
| 82607 | 160 | 159 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 295 | 289 | $2K |
| 96361 | Intravenous infusion, hydration; each additional hour | 377 | 339 | $2K |
| 84100 | 389 | 360 | $2K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 30 | 25 | $2K |
| 0012A | 39 | 39 | $2K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 379 | 320 | $2K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 359 | 322 | $1K |
| 0011A | 31 | 31 | $1K | |
| 81003 | 429 | 409 | $1K | |
| 87077 | 172 | 164 | $1K | |
| 73610 | 58 | 56 | $1K | |
| 73630 | 106 | 99 | $1K | |
| 87081 | 185 | 181 | $1K | |
| 85652 | 385 | 346 | $1K | |
| 87040 | 97 | 50 | $1K | |
| 84460 | 120 | 116 | $952.20 | |
| 86618 | 34 | 33 | $892.29 | |
| 87186 | 121 | 115 | $867.39 | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 15 | 13 | $852.39 |
| 87807 | 56 | 56 | $848.15 | |
| 85379 | 94 | 89 | $789.05 | |
| 86140 | 308 | 270 | $786.74 | |
| 73130 | 59 | 55 | $691.02 | |
| 73564 | 25 | 25 | $657.19 | |
| 71045 | Radiologic examination, chest; single view | 102 | 89 | $635.58 |
| 93971 | 12 | 12 | $628.23 | |
| 83615 | 82 | 66 | $580.51 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 13 | 12 | $556.17 |
| 82150 | 110 | 102 | $501.14 | |
| 83721 | 38 | 38 | $476.13 | |
| 82570 | 61 | 58 | $443.79 | |
| 84153 | 12 | 12 | $318.16 | |
| 87184 | 41 | 39 | $298.22 | |
| J7030 | Infusion, normal saline solution , 1000 cc | 493 | 448 | $250.21 |
| 90714 | 42 | 42 | $237.31 | |
| 82043 | 29 | 27 | $214.73 | |
| 82746 | 15 | 15 | $211.68 | |
| 83718 | 26 | 26 | $183.68 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 458 | 425 | $175.64 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 341 | 310 | $167.84 |
| 82248 | 18 | 18 | $150.34 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 14 | 13 | $108.49 |
| 94664 | 19 | 17 | $102.59 | |
| J2704 | Injection, propofol, 10 mg | 280 | 194 | $87.76 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 195 | 188 | $58.60 |
| 94760 | 63 | 50 | $47.47 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 28 | 28 | $43.52 |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 146 | 125 | $43.29 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 29 | 29 | $42.10 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 345 | 300 | $41.47 |
| 82948 | 16 | 12 | $20.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 42 | 37 | $9.23 |